1. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27(13):2278-2287.
2. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349(10):931-940.
3. Lee SG, Jeng LB, Saliba F, et al. Efficacy and safety of evero- limus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of 2 randomized controlled trials. Transplantation. 2021;105(7):1564-1575.
4. Fischer L, Saliba F, Kaiser GM, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with re- duced tacrolimus: follow-up results from a randomized, multi- center study. Transplantation. 2015;99(7):1455-1462.
5. Saliba F, De Simone P, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a random- ized, multicenter study. Am J Transplant. 2013;13(7):1734-1745.
6. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12(11):3008-3020.
7. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical phar- macokinetics of everolimus. Clin Pharmacokinet. 2004;43(2): 83-95.
8. Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther. 2001;70(3):247-254.
9. Moes DJ, Press RR, den Hartigh J, van der Straaten T, de Fijter JW, Guchelaar HJ. Population pharmacokinetics and phar- macogenetics of everolimus in renal transplant patients. Clin Pharmacokinet. 2012;51(7):467-480.
10. Kagaya H, Niioka T, Saito M, et al. Prediction of tacrolimus ex- posure by CYP3A5 genotype and exposure of co-administered everolimus in Japanese renal transplant recipients. Int J Mol Sci. 2018;19(3):882.
11. Matsuo S, Imai E, Horio M, et al. Revised equations for esti- mated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982-992.
12. Uemura O, Nagai T, Ishikura K, et al. Creatinine-based equa- tion to estimate the glomerular filtration rate in Japanese chil- dren and adolescents with chronic kidney disease. Clin Exp Nephrol. 2014;18(4):626-633.
13. Gotoh Y, Uemura O, Fujita N, et al. Validation of the esti- mated glomerular filtration rate equation for Japanese children younger than 2 years. Clin Exp Nephrol. 2022;26(3):266-271.
14. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303-332.
15. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction- corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143-151.
16. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503-512.
17. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558-569.
18. Nakagita K, Wada K, Terada Y, et al. Effect of fluconazole on the pharmacokinetics of everolimus and tacrolimus in a heart transplant recipient: case report. Int J Clin Pharmacol Ther. 2018;56(6):270-276.
19. Lemaitre F, Bezian E, Goldwirt L, et al. Population pharmacoki- netics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. Ther Drug Monit. 2012;34(6): 686-694.
20. Itohara K, Yano I, Nakagawa S, et al. Extrapolation of physi- ologically based pharmacokinetic model for tacrolimus from renal to liver transplant patients. Drug Metab Pharmacokinet. 2022;42:100423.
21. Fukatsu S, Yano I, Igarashi T, et al. Population pharmacokinet- ics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57(6–7):479-484.
22. Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage RC. Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. Bone Marrow Transplant. 2001;28(8):753-758.
23. Andrews LM, Hesselink DA, van Schaik RHN, et al. A popula- tion pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2019;85(3):601-615.
24. Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol. 2006;17(9):2363-2367.
25. Wolbold R, Klein K, Burk O, et al. Sex is a major determi- nant of CYP3A4 expression in human liver. Hepatology. 2003;38(4):978-988.
26. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44(2):275-283.
27. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cy- tochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004;199(3):193-209.
28. Schirmer M, Rosenberger A, Klein K, et al. Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics. 2007;8(5): 443-453.
29. Ahn JE, Birnbaum AK, Brundage RC. Inherent correla- tion between dose and clearance in therapeutic drug mon- itoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn. 2005;32(5–6):703-718.
30. Shoji K, Miyairi I, Inoue E, Fukuda A, Sakamoto S, Kasahara M. Graft-to-recipient weight ratio associated with tacrolimus metabolism following pediatric living donor liver transplantations. J Pediatr Pharmacol Ther. 2019;24(2):138-147.
31. Jacobsen W, Serkova N, Hausen B, Morris RE, Benet LZ, Christians U. Comparison of the in vitro metabolism of the mac- rolide immunosuppressants sirolimus and RAD. Transplant Proc. 2001;33(1–2):514-515.
32. Kovarik JM, Hartmann S, Figueiredo J, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy. 2002;22(2):154-159.